TECH vs TXG · P/E 65, rev $1.22B vs rev $610.8M
Bio-Techne Corp (TECH) versus 10X Genomics Inc (TXG) — a side-by-side from cached financials, not a winner call.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Latest reported TXG revenue for 2024-12-31 was $610.8M. Net income was -$182.6M. Revenue was down 1.3% from 2023-12-31 to 2024-12-31. TXG currently screens at market cap $4.08B.
TECH currently screens at market cap $8.49B and trailing P/E 65.2. TXG currently screens at market cap $4.08B.
Not investment advice. Open the TECH and TXG stock pages for the full models.
Not investment advice.